Citation: Huijiao Fu, Peiqin Liang, Qianwen Chen, Yan Wang, Guang Li, Xuzi Cai, Shengtao Wang, Kun Chen, Shengying Shi, Zhiqiang Yu, Xuefeng Wang. COX-2 blocking therapy in cisplatin chemosensitization of ovarian cancer: An allicin-based nanomedicine approach[J]. Chinese Chemical Letters, ;2024, 35(8): 109241. doi: 10.1016/j.cclet.2023.109241 shu

COX-2 blocking therapy in cisplatin chemosensitization of ovarian cancer: An allicin-based nanomedicine approach

Huijiao Fu ^{a, 1} ,
Peiqin Liang ^{a, 1} ,
Qianwen Chen ^{a, 1} ,
Yan Wang ^b ,
Guang Li ^a ,
Xuzi Cai ^a ,
Shengtao Wang ^c ,
Kun Chen ^d ,
Shengying Shi ^{e, *,} ,
Zhiqiang Yu ^{f, *,} ,
Xuefeng Wang ^{a, *,}

a.
Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, China
b.
Department of Obstetrics and Gynecology, Huizhou Central People’s Hospital, Huizhou 516001, China
c.
Affiliated Foshan Maternity & Child Healthcare Hospital, Southern Medical University (Foshan Maternity & Child Healthcare Hospital), Foshan 528000, China
d.
Guangdong Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
e.
Department of Nursing, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
f.
Department of Laboratory Medicine, Dongguan Institute of Clinical Cancer Research, The Tenth Affiliated Hospital of Southern Medical University (Dongguan People's Hospital), Dongguan 523018, China

nfyykyb@126.com

yuzq@smu.edu.cn

douwangxuefeng@163.com

Received Date: 24 August 2023
Revised Date: 17 October 2023
Accepted Date: 20 October 2023
Available Online: 2 November 2023

Figures(4)

Recently, the utilization of nonsteroidal anti-inflammatory drugs (NSAIDs) to sensitize cisplatin (CDDP) has gained substantial traction in the treatment of ovarian cancer (OC). However, even widely employed NSAIDs such as celecoxib and naproxen carry an elevated risk of cardiovascular events, notably thrombosis. Furthermore, the diminished sensitivity to CDDP therapy in OC is multifactorial, rendering the application of NSAIDs only partially effective due to their cyclooxygenase-2 (COX-2) inhibiting mechanism. Hence, in this study, reactive oxygen species (ROS)-responsive composite nano-hydrangeas loaded with the Chinese medicine small molecule allicin and platinum(Ⅳ) prodrug (DTP@AP NPs) were prepared to achieve comprehensive chemosensitization. On one front, allicin achieved COX-2 blocking therapy, encompassing the inhibition of proliferation, angiogenesis and endothelial mesenchymal transition (EMT), thereby mitigating the adverse impacts of CDDP chemotherapy. Simultaneously, synergistic chemosensitization was achieved from multifaceted mechanisms by decreasing CDDP inactivation, damaging mitochondria and inhibiting DNA repair. In essence, these findings provided an optimized approach for synergizing CDDP with COX-2 inhibitors, offering a promising avenue for enhancing OC treatment outcomes.
- COX-2 blocking therapy,
- CDDP,
- Chemosensitization,
- Allicin,
- Ovarian cancer
1. [1]
  X. Cai, S. Shi, G. Chen, et al., Acta Biomater. 158 (2022) 560–570. doi: 10.3390/ma15020560
2. [2]
  M. Song, M. Cui, K. Liu, Eur. J. Med. Chem. 232 (2022) 114205. doi: 10.1016/j.ejmech.2022.114205
3. [3]
  J. Yang, T. Su, H. Zou, et al., Angew. Chem. Int. Ed. 61 (2022) e202211136. doi: 10.1002/anie.202211136
4. [4]
  S.P. Blagden, S. Nicum, Lancet 397 (2021) 254–256. doi: 10.1016/S0140-6736(21)00128-8
5. [5]
  A. Gartung, J. Yang, V.P. Sukhatme, et al., Proc. Natl. Acad. Sci. U. S. A. 116 (2019) 1698–1703. doi: 10.1073/pnas.1803999116
6. [6]
  J.R. Neil, K.M. Johnson, R.A. Nemenoff, et al., Carcinogenesis 29 (2008) 2227–2235. doi: 10.1093/carcin/bgn202
7. [7]
  R. Fujⅱ, Y. Imanishi, K. Shibata, et al., J. Exp. Clin. Cancer Res. 33 (2014) 40. doi: 10.1186/1756-9966-33-40
8. [8]
  H.C. Lao, J.K. Akunda, K.S. Chun, et al., Carcinogenesis 33 (2012) 2293–2300. doi: 10.1093/carcin/bgs267
9. [9]
  K. Mohankumar, S. Sridharan, S. Pajaniradje, et al., Biomed. Pharmacother. 74 (2015) 178–186. doi: 10.1016/j.biopha.2015.07.024
10. [10]
  H. Gungor, N. Ilhan, H. Eroksuz, Biomed. Pharmacother. 102 (2018) 221–229. doi: 10.1016/j.biopha.2018.03.066
11. [11]
  J. Huang, Y. Xu, H. Xiao, et al., ACS Nano 13 (2019) 7036–7049. doi: 10.1021/acsnano.9b02149
12. [12]
  G. Ferrandina, G.F. Zannoni, F.O. Ranelletti, et al., Gynecol. Oncol. 95 (2004) 46–51. doi: 10.1016/j.ygyno.2004.07.005
13. [13]
  G. Ferrandina, L. Lauriola, G.F. Zannoni, et al., Ann. Oncol. 13 (2002) 1205–1211. doi: 10.1093/annonc/mdf207
14. [14]
  M.P. Garrido, I. Hurtado, M. Valenzuela-Valderrama, et al., Cancers 11 (2019) 1970. doi: 10.3390/cancers11121970
15. [15]
  C. Yang, L. Xing, X. Chang, et al., Mol. Pharm. 17 (2020) 1300–1309. doi: 10.1021/acs.molpharmaceut.9b01318
16. [16]
  L. Xing, C. Yang, D. Zhao, et al., J. Control. Rel. 331 (2021) 460–471. doi: 10.1016/j.jconrel.2021.01.037
17. [17]
  J. Zang, B. Zhang, Y. Wang, et al., Bioorg. Chem. 120 (2022) 105633. doi: 10.1016/j.bioorg.2022.105633
18. [18]
  A.M. Schjerning, P. McGettigan, G. Gislason, Nat. Rev. Cardiol. 17 (2020) 574–584. doi: 10.1038/s41569-020-0366-z
19. [19]
  J. Liu, S. Wang, Y. Zhang, et al., Thorac. Cancer 6 (2015) 561–569. doi: 10.1111/1759-7714.12270
20. [20]
  A. Mondal, S. Banerjee, S. Bose, et al., Pharmacol. Res. 175 (2022) 105837. doi: 10.1016/j.phrs.2021.105837
21. [21]
  A. Balsamo, I. Coletta, A. Guglielmotti, et al., Eur. J. Med. Chem. 37 (2002) 585–594. doi: 10.1016/S0223-5234(02)01385-5
22. [22]
  W. Huang, C. Yao, Y. Liu, et al., Front. Physiol. 11 (2020) 587674. doi: 10.3389/fphys.2020.587674
23. [23]
  S. Xu, Y. Liao, Q. Wang, et al., Crit. Rev. Food. Sci. Nutr. 63 (2023) 7722–7748. doi: 10.1080/10408398.2022.2049691
24. [24]
  Y. Wang, J. Zhan, J. Huang, et al., Interdiscipl. Med. 1 (2023) e20220005. doi: 10.1002/INMD.20220005
25. [25]
  S. Wang, K. Yu, Z. Yu, et al., Chin. Chem. Lett. 34 (2023) 108184. doi: 10.1016/j.cclet.2023.108184
26. [26]
  K. Gong, J. Liao, J. Lin, et al., Chin. Chem. Lett. 35 (2024) 108888. doi: 10.1016/j.cclet.2023.108888
27. [27]
  Q. Meng, H. Hu, X. Jing, et al., J. Control. Rel. 340 (2021) 102–113. doi: 10.1016/j.jconrel.2021.10.027
28. [28]
  Y. Cao, Y. Chen, T. Yu, et al., Theranostics 8 (2018) 1327–1339. doi: 10.7150/thno.21492
29. [29]
  J.J. Rennick, A. Johnston, R.G. Parton, Nat. Nanotechnol. 16 (2021) 266–276. doi: 10.1038/s41565-021-00858-8
30. [30]
  J. Liu, Z. Wu, Y. Liu, et al., J. Nanobiotechnol. 20 (2022) 213. doi: 10.1186/s12951-022-01435-4
31. [31]
  D. Che, S. Zhang, Z. Jing, et al., Mol. Immunol. 90 (2017) 197–210. doi: 10.1016/j.molimm.2017.06.018
32. [32]
  M.A. Nieto, R.Y. Huang, R.A. Jackson, et al., Cell 166 (2016) 21–45. doi: 10.1016/j.cell.2016.06.028
33. [33]
  W. Wang, X. He, X. Wang, et al., Chin. Chem. Lett. 35 (2024) 108656. doi: 10.1016/j.cclet.2023.108656
34. [34]
  D. Qi, L. Xing, L. Shen, et al., Chin. Chem. Lett. 33 (2022) 4595–4599. doi: 10.1016/j.cclet.2022.03.105
35. [35]
  W. Song, Z. Tang, N. Shen, et al., J. Control. Rel. 231 (2016) 94–102. doi: 10.1016/j.jconrel.2016.02.039
36. [36]
  N. Pandey, G. Tyagi, P. Kaur, et al., Cell Physiol. Biochem. 54 (2020) 748–766. doi: 10.33594/000000253
37. [37]
  S.P. Tang, X.L. Mao, Y.H. Chen, et al., Front. Immunol. 13 (2022) 870239. doi: 10.3389/fimmu.2022.870239
38. [38]
  A.T. Hoye, J.E. Davoren, P. Wipf, et al., Acc. Chem. Res. 41 (2008) 87–97. doi: 10.1021/ar700135m
39. [39]
  M. Luo, Z.Q. Yang, J.C. Huang, et al., Cell Biol. Int. 44 (2020) 433–445. doi: 10.1002/cbin.11244
40. [40]
  J.L. Hopkins, L. Lan, L. Zou, Genes Dev. 36 (2022) 278–293. doi: 10.1101/gad.349431.122
41. [41]
  E. Freund, K.R. Liedtke, L. Miebach, et al., Cancers 12 (2020) 122. doi: 10.3390/cancers12010122
42. [42]
  N. Erez, S. Glanz, Y. Raz, et al., Biochem. Biophys. Res. Commun. 437 (2013) 397–402. doi: 10.1016/j.bbrc.2013.06.089
43. [43]
  H.F. Chen, H.C. Chuang, T.H. Tan, Int. J. Mol. Sci. 20 (2019) 2668. doi: 10.3390/ijms20112668
44. [44]
  Q.N. Wu, Y.F. Liao, Y.X. Lu, et al., Cancer Lett. 412 (2018) 243–255. doi: 10.1016/j.canlet.2017.10.007
45. [45]
  G. Momtazi, B.N. Lambrecht, J.R. Naranjo, et al., Am. J. Physiol. Lung Cell. Mol. Physiol. 316 (2019) L456–L469. doi: 10.1152/ajplung.00335.2018
46. [46]
  C. Rebe, F. Ghiringhelli, Cancers 12 (2020) 1791. doi: 10.3390/cancers12071791
47. [47]
  C.S. Melincovici, A.B. Bosca, S. Susman, et al., Rom. J. Morphol. Embryol. 59 (2018) 455–467.
48. [48]
  L.T. Mikalsen, H.P. Dhakal, O.S. Bruland, et al., Anticancer Res. 31 (2011) 4053–4060.
49. [49]
  W. Rozpedek, D. Pytel, B. Mucha, et al., Curr. Mol. Med. 16 (2016) 533–544. doi: 10.2174/1566524016666160523143937
50. [50]
  A. Payapilly, R. Guilbert, T. Descamps, et al., Cell Rep. 37 (2021) 109979. doi: 10.1016/j.celrep.2021.109979
51. [51]
  G. Bi, J. Liang, M. Zhao, et al., Mol. Ther. Nucleic Acids 28 (2022) 366–386. doi: 10.1016/j.omtn.2022.03.020
52. [52]
  S. Su, G. Chhabra, C.K. Singh, et al., Transl. Oncol. 16 (2022) 101332. doi: 10.1016/j.tranon.2021.101332
1. [1]
  Huijie An , Chen Yang , Zhihui Jiang , Junjie Yuan , Zhongming Qiu , Longhao Chen , Xin Chen , Mutu Huang , Linlang Huang , Hongju Lin , Biao Cheng , Hongjiang Liu , Zhiqiang Yu . Luminescence-activated Pt(Ⅳ) prodrug for in situ triggerable cancer therapy. Chinese Chemical Letters, 2024, 35(7): 109134-. doi: 10.1016/j.cclet.2023.109134
2. [2]
  Mengjuan Sun , Muye Zhou , Yifang Xiao , Hailei Tang , Jinhua Chen , Ruitao Zhang , Chunjiayu Li , Qi Ya , Qian Chen , Jiasheng Tu , Qiyue Wang , Chunmeng Sun . Reversibly size-switchable polyion complex micelles for antiangiogenic cancer therapy. Chinese Chemical Letters, 2024, 35(7): 109110-. doi: 10.1016/j.cclet.2023.109110
3. [3]
  Qiang Li , Jiangbo Fan , Hongkai Mu , Lin Chen , Yongzhen Yang , Shiping Yu . Nucleus-targeting orange-emissive carbon dots delivery adriamycin for enhanced anti-liver cancer therapy. Chinese Chemical Letters, 2024, 35(6): 108947-. doi: 10.1016/j.cclet.2023.108947
4. [4]
  Yihan Zhou , Duo Gao , Yaying Wang , Li Liang , Qingyu Zhang , Wenwen Han , Jie Wang , Chunliu Zhu , Xinxin Zhang , Yong Gan . Worm-like micelles facilitate the intestinal mucus diffusion and drug accumulation for enhancing colorectal cancer therapy. Chinese Chemical Letters, 2024, 35(6): 108967-. doi: 10.1016/j.cclet.2023.108967
5. [5]
  Ling-Ling Wu , Xiangchuan Meng , Qingyang Zhang , Xiaowan Han , Feiya Yang , Qinghua Wang , Hai-Yu Hu , Nianzeng Xing . Heavy-atom engineered hypoxia-responsive probes for precisive photoacoustic imaging and cancer therapy. Chinese Chemical Letters, 2024, 35(4): 108663-. doi: 10.1016/j.cclet.2023.108663
6. [6]
  Lin Li , Bingjun Sun , Jin Sun , Lin Chen , Zhonggui He . Binary prodrug nanoassemblies combining chemotherapy and ferroptosis activation for efficient triple-negative breast cancer therapy. Chinese Chemical Letters, 2024, 35(10): 109538-. doi: 10.1016/j.cclet.2024.109538
7. [7]
  Wenjia Wang , Xingyue He , Xiaojie Wang , Tiantian Zhao , Osamu Muraoka , Genzoh Tanabe , Weijia Xie , Tianjiao Zhou , Lei Xing , Qingri Jin , Hulin Jiang . Glutathione-depleted cyclodextrin pseudo-polyrotaxane nanoparticles for anti-inflammatory oxaliplatin (Ⅳ) prodrug delivery and enhanced colorectal cancer therapy. Chinese Chemical Letters, 2024, 35(4): 108656-. doi: 10.1016/j.cclet.2023.108656
8. [8]
  Yang Liu , Yan Liu , Kaiyin Yang , Zhiruo Zhang , Wenbo Zhang , Bingyou Yang , Hua Li , Lixia Chen . A selective HK2 degrader suppresses SW480 cancer cell growth by degrading HK2. Chinese Chemical Letters, 2024, 35(8): 109264-. doi: 10.1016/j.cclet.2023.109264
9. [9]
  Xuejian Xing , Pan Zhu , E Pang , Shaojing Zhao , Yu Tang , Zheyu Hu , Quchang Ouyang , Minhuan Lan . D-A-D-structured boron-dipyrromethene with aggregation-induced enhanced phototherapeutic efficiency for near-infrared fluorescent and photoacoustic imaging-guided synergistic photodynamic and photothermal cancer therapy. Chinese Chemical Letters, 2024, 35(10): 109452-. doi: 10.1016/j.cclet.2023.109452
10. [10]
  Ke Gong , Jinghan Liao , Jiangtao Lin , Quan Wang , Zhihua Wu , Liting Wang , Jiali Zhang , Yi Dong , Yourong Duan , Jianhua Chen . Mitochondria-targeted nanoparticles overcome chemoresistance via downregulating BACH1/CD47 axis in ovarian carcinoma. Chinese Chemical Letters, 2024, 35(5): 108888-. doi: 10.1016/j.cclet.2023.108888
11. [11]
  Junjie Wang , Yan Wang , Zhengdong Li , Changqiang Xie , Musammir Khan , Xingzhou Peng , Fabiao Yu . Triphenylamine-AIEgens photoactive materials for cancer theranostics. Chinese Chemical Letters, 2024, 35(6): 108934-. doi: 10.1016/j.cclet.2023.108934
12. [12]
  Haijing Cui , Weihao Zhu , Chuning Yue , Ming Yang , Wenzhi Ren , Aiguo Wu . Recent progress of ultrasound-responsive titanium dioxide sonosensitizers in cancer treatment. Chinese Chemical Letters, 2024, 35(10): 109727-. doi: 10.1016/j.cclet.2024.109727
13. [13]
  Yiran Tao , Chunlei Dai , Zhaoxiang Xie , Xinru You , Kaiwen Li , Jun Wu , Hai Huang . Redox responsive polymeric nanoparticles enhance the efficacy of cyclin dependent kinase 7 inhibitor for enhanced treatment of prostate cancer. Chinese Chemical Letters, 2024, 35(8): 109170-. doi: 10.1016/j.cclet.2023.109170
14. [14]
  Xiangqian Cao , Chenkai Yang , Xiaodong Zhu , Mengxin Zhao , Yilin Yan , Zhengnan Huang , Jinming Cai , Jingming Zhuang , Shengzhou Li , Wei Li , Bing Shen . Synergistic enhancement of chemotherapy for bladder cancer by photothermal dual-sensitive nanosystem with gold nanoparticles and PNIPAM. Chinese Chemical Letters, 2024, 35(8): 109199-. doi: 10.1016/j.cclet.2023.109199
15. [15]
  Boran Cheng , Lei Cao , Chen Li , Fang-Yi Huo , Qian-Fang Meng , Ganglin Tong , Xuan Wu , Lin-Lin Bu , Lang Rao , Shubin Wang . Fluorine-doped carbon quantum dots with deep-red emission for hypochlorite determination and cancer cell imaging. Chinese Chemical Letters, 2024, 35(6): 108969-. doi: 10.1016/j.cclet.2023.108969
16. [16]
  Yuanyi Zhou , Ke Ma , Jinfeng Liu , Zirun Zheng , Bo Hu , Yu Meng , Zhizhong Li , Mingshan Zhu . Is reactive oxygen species the only way for cancer inhibition over single atom nanomedicine? Autophagy regulation also works. Chinese Chemical Letters, 2024, 35(6): 109056-. doi: 10.1016/j.cclet.2023.109056
17. [17]
  Jing Chen , Peisi Xie , Pengfei Wu , Yu He , Zian Lin , Zongwei Cai . MALDI coupled with laser-postionization and trapped ion mobility spectrometry contribute to the enhanced detection of lipids in cancer cell spheroids. Chinese Chemical Letters, 2024, 35(4): 108895-. doi: 10.1016/j.cclet.2023.108895
18. [18]
  Yu Qin , Mingyang Huang , Chenlu Huang , Hannah L. Perry , Linhua Zhang , Dunwan Zhu . O₂-generating multifunctional polymeric micelles for highly efficient and selective photodynamic-photothermal therapy in melanoma. Chinese Chemical Letters, 2024, 35(7): 109171-. doi: 10.1016/j.cclet.2023.109171
19. [19]
  Lixian Fu , Yiyun Tan , Yue Ding , Weixia Qing , Yong Wang . Water–soluble and polarity–sensitive near–infrared fluorescent probe for long–time specific cancer cell membranes imaging and C. Elegans label. Chinese Chemical Letters, 2024, 35(4): 108886-. doi: 10.1016/j.cclet.2023.108886
20. [20]
  Caixia Li , Yi Qiu , Yufeng Zhao , Wuliang Feng . Self assembled electron blocking and lithiophilic interface towards dendrite-free solid-state lithium battery. Chinese Chemical Letters, 2024, 35(4): 108846-. doi: 10.1016/j.cclet.2023.108846

Get Citation

PDF

XML

Metrics

PDF Downloads(3)
Abstract views(304)
HTML views(11)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142